Pramlintide side effects and risks

Reported side effects

• Nausea: Type 1 label pool: 48% versus 17% placebo; type 2: 28% versus 12%., moderate. Persistent nausea needs clinician review; treatment may need to be reduced or stopped. (source)
• Vomiting: Type 1: 11% versus 7% placebo; type 2: 8% versus 4%., moderate. Repeated vomiting or inability to eat needs prompt review of fluids, glucose and insulin. (source)
• Appetite loss: Type 1: 17% versus 2% placebo; type 2: 9% versus 2%., moderate. Eating less changes mealtime insulin needs; monitor intake and glucose together. (source)
• Headache: Type 2 label pool: 13% versus 7% placebo., mild. Check glucose; persistent or severe headache needs assessment. (source)
• Severe low blood sugar with insulin: Type 1, first 3 months without an initial insulin cut: medically assisted events in 7.3% versus 3.3% placebo., serious. Starting treatment requires your clinician to reduce mealtime insulin, with frequent blood sugar checks. (source)
• Stomach pain: Type 2: 8% versus 7% placebo., moderate. Severe or persistent pain needs prompt assessment, especially with vomiting. (source)
• Fatigue: Type 1 and type 2 label pools: 7% versus 4% placebo., mild (source)
• Dizziness: Type 1: 5% versus 4% placebo; type 2: 6% versus 4%., moderate. Check glucose and avoid driving while symptoms persist. (source)
• Injection-site reactions: Postmarketing reports; frequency cannot be estimated., mild. Use room-temperature solution, rotate sites and check injection technique. (source)
• Pancreatitis: Reported after approval; frequency and causation are uncertain., serious. Severe persistent upper-abdominal pain, especially with vomiting, needs urgent assessment. (source)

Stop and get help if

• Confusion, seizure, fainting, or low blood sugar that does not recover: Follow your prescribed rescue plan. Call emergency services for severe symptoms or failure to recover.
• Severe persistent upper-belly pain, especially with vomiting: Stop pramlintide and seek urgent care for possible pancreatitis.
• Swollen face or throat, trouble breathing, or widespread hives: Stop the injection and seek emergency care.
• Repeated vomiting or inability to keep down food or fluids: Get urgent help with blood sugar, fluids and insulin. Do not inject pramlintide if you cannot eat.

Who should avoid it

• under18: Pediatric safety and effectiveness are not established; the label advises against pediatric use.
• pregnant: Human safety data are limited; rat studies found birth defects at high exposures.
• breastfeeding: Transfer into human milk, infant effects and milk production are unknown.
• tryingToConceive: Plan diabetes care with your clinician before pregnancy.
• gastroparesis: The label rules out use with gastroparesis, meaning slow stomach emptying. Pramlintide slows it further.
• other: The label rules out use if you cannot feel low blood sugar warning signs.
• other: Avoid after severe low blood sugar needing help within the past 6 months, or when episodes recur.
• other: The label rules out use after a serious allergy to pramlintide or any ingredient.
• other: The label excludes people with HbA1c above 9%, unreliable glucose checks or inability to follow insulin adjustments. HbA1c measures long-term blood sugar.
• eatingDisorderHistory: Appetite loss and nausea may worsen restrictive eating; this is not a label contraindication.
• pancreatitisHistory: Pancreatitis has been reported after approval; prior pancreatitis needs review before use.
• kidneyDisease: Kidney disease needs clinician review. No label dose change for creatinine clearance 15–89 mL/min. End-stage kidney disease has not been studied.
• liverDisease: Liver impairment has not been studied.
• surgeryPlanned: Fasting and illness affect dosing and insulin needs. If interrupted, the label requires restarting the initiation schedule.
• other: Visual or hand-function problems can cause dosing errors; the label calls for extra caution.
• other: Migraine-like attacks occurred in an IV provocation study. The risk with routine SC doses is not established.
• diabetes: Pramlintide supplements insulin; it cannot replace it. Mealtime insulin must be adjusted with close glucose monitoring.
• testedAthlete: No pramlintide-specific 2026 ruling was found. Confirm with the sport’s anti-doping body; accompanying insulin is prohibited.
• other: The label excludes people who need medicines that stimulate gut movement.

Interactions

• Insulin: Severe low blood sugar risk rises. When starting pramlintide, your clinician must reduce mealtime insulin and plan blood sugar checks. Inject separately; never mix.
• Sulfonylureas and meglitinides: These increase insulin release and can add to low-glucose risk; reassess the glucose-lowering plan.
• Time-sensitive oral medicines: For medicines needing rapid or threshold absorption, the label says at least 1 hour before or 2 hours after pramlintide.
• Warfarin and other critical oral medicines: Stomach emptying is delayed. No specific warfarin interaction trial was found; review timing and condition-specific monitoring.
• Medicines changing gut movement: The label advises against use with drugs that change gut movement or slow nutrient absorption.
• GLP-1 and GIP/GLP-1 drugs: Fullness and delayed stomach emptying may add up. 3 cases with type 1 diabetes and obesity leave combination safety uncertain.
• Other amylin agonists: Shared amylin effects may add nausea and slow stomach emptying. Cell studies do not establish combination safety.
• Drugs that increase low-glucose risk: These medicines can raise low blood sugar risk when taken together.
• Drugs that mask low-glucose symptoms: These can hide low blood sugar warning signs.
• Metreleptin: Obesity trials tested this pair, but neutralizing leptin antibodies raised concern. The combination has no obesity approval.

Product quality risks

• No independent study testing online pramlintide products or counterfeit Symlin pens was located.
• Other online peptide tests show why identity, content and contamination matter; those rates cannot be assigned to pramlintide.
• In three online semaglutide samples, purity was 7–14% and content 29–39% above the label; one contained elevated endotoxin. This was not pramlintide.
• FDA warns that poor compounding can cause contamination or too much or too little active drug.
• A research-use label and an HPLC purity number do not establish an injectable product’s sterility or dose.